Drug Development Disruption
The skyrocketing costs of pharmaceutical drug development create a risk-averse culture in the industry. Ingmar shares a compelling example of how AI can drastically reduce testing efforts, suggesting innovative candidates that lead to significant breakthroughs. The conversation shifts to the effectiveness of shallow versus deep machine learning techniques, highlighting the potential for remarkable efficiency gains in drug discovery.In this clip
From this podcast
Super Data Science: ML & AI Podcast with Jon Krohn
739: AI is Eating Biology and Chemistry — with Dr. Ingmar Schuster
Related Questions